TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Bio Inc.

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on TELA Bio, with a price target of $3.00. Takkinen covers the ...

Market Cap	$47.94M	P/E Ratio	N/A
52W High	$3.10	52W Low	$0.87
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	16.7%	52W Position	12.8%
Overall Score	41	Value Score	50
Quality Score	55	Technical Score	18

EPS Current Est	$-0.84	EPS Next Est	$-0.49
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TELA	$1.15	+1.77%	113.96K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TELA	$1.15	+1.8%	113.96K
3
4
5
6

TELA

TELA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get TELA Bio Inc. Data in Excel

Get TELA Bio Inc. Data in Excel